NASDAQ:INVA - Innoviva Stock Price, Price Target & More

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Innoviva Inc (NASDAQ:INVA) announced its quarterly earnings data on Thursday, April, 26th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by $0.23. The biotechnology company had revenue of $52.40 million for the quarter, compared to analysts' expectations of $71.84 million. Innoviva had a net margin of 64.11% and a negative return on equity of 63.57%. The business's quarterly revenue was up 29.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.19 EPS. View Innoviva's Earnings History.

Innoviva is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Innoviva.

6 Wall Street analysts have issued 12 month target prices for Innoviva's stock. Their predictions range from $8.00 to $16.00. On average, they expect Innoviva's stock price to reach $13.20 in the next twelve months. This suggests that the stock has a possible downside of 6.4%. View Analyst Ratings for Innoviva.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Innoviva include Catalent (CTLT), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Madrigal Pharmaceuticals (MDGL) and Array Biopharma (ARRY).

News articles about INVA stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Innoviva earned a news impact score of 0.12 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.18 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Innoviva's stock is owned by a number of of institutional and retail investors. Top institutional investors include Campbell & CO Investment Adviser LLC (0.04%) and Fox Run Management L.L.C. (0.02%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.

INVA stock was sold by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie and Michael W Aguiar. View Insider Buying and Selling for Innoviva.

INVA stock was purchased by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Innoviva.

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of INVA stock can currently be purchased for approximately $14.11.

Innoviva has a market capitalization of $1.51 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.

Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]